1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

03 Feb 2026
Admin
News Article

Lupin Partners with TB Alliance to Advance Telacebec for TB and Other Mycobacterial Diseases

Lupin Limited has announced a strategic collaboration with TB Alliance, a nonprofit drug developer, to advance the clinical development and commercialization of Telacebec (formerly Q203).

Telacebec is an investigational drug being developed for the treatment of:

Tuberculosis (TB)
Leprosy
Buruli ulcer

The collaboration aims to accelerate development and support global access to improved therapies for these neglected mycobacterial diseases.

How the Collaboration Is Structured

Under the agreement:

TB Alliance will continue to lead Telacebec’s clinical development
Lupin will contribute expertise in manufacturing, regulatory affairs, and supply chain
Both parties will jointly support commercialization efforts

The partnership combines TB Alliance’s drug development experience with Lupin’s global manufacturing scale and distribution network.

Why Telacebec Matters?

TB, leprosy, and Buruli ulcer continue to pose major public health challenges, particularly in low- and middle-income countries.

Current treatments:

Require long, complex regimens
Can have significant side effects
Face growing concerns around drug resistance

Telacebec represents a potential next-generation therapy that could help shorten, simplify, or improve treatment outcomes across multiple mycobacterial diseases.

What the Companies Are Saying?

Ramesh Swaminathan, Executive Director, Global CFO, and Head of IT and API Plus SBU at Lupin, said the collaboration reflects Lupin’s commitment to addressing high unmet medical needs.

Mel Spigelman, MD, President and CEO of TB Alliance, said Telacebec has the potential to transform treatment for long-neglected diseases and that the partnership strengthens the path toward global access.

About Lupin

Lupin Limited is a global pharmaceutical company headquartered in Mumbai, India.

The company operates in over 100 markets and focuses on:

Branded and generic formulations
Complex generics
Biotechnology products
Active pharmaceutical ingredients (APIs)

About TB Alliance

TB Alliance is a nonprofit organization focused on developing faster-acting and affordable drug regimens for TB and related mycobacterial diseases.

The organization works with global partners to ensure equitable access to improved treatments worldwide.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!